Maximize Your Returns with AI-Powered IBB Insights

---

Trade smarter with daily optimized IBB trades + news analysis

BlackRock Institutional Trust Company N.A. - iShares Biotechnology ETF

tech

U.S. News compares companies to their industry peers based on a variety of company fundamentals, performance metrics and investor preferences to help you find the right stocks for your investing

US News     Dec 13, 2022

IBB: Targeting A Buy Point Heading Into Year-End (NASDAQ:IBB) - Seeking Alpha

Venture away from tech-related stocks, and you are going to find a healthy dose of red on your 2023 performance screen. Relative losses are even worse for small-sized funds. Interestingly, both the cap-weighted iShares Biotechnology ETF (NASDAQ:IBB) and the equally weighted SPDR S&P Biotech ETF (XBI) have performed about the same so far in 2023, illustrated by the ETF performance heat map below.

seekingalpha.com     Nov 22, 2023

Should You Invest in the SPDR S&P Biotech ETF (XBI)? - Yahoo Finance

Launched on 01/31/2006, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

Yahoo     Nov 20, 2023

😊 Taking on analysts' expectations and winning: Adma Biologics Inc ... - SETE News

Adma Biologics Inc (NASDAQ: ADMA) stock jumped 1.51% on Monday to $4.03 against a previous-day closing price of $3.97. With 2.77 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.08 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.0700 whereas the lowest price it dropped to was $3.9300. The 52-week range on ADMA shows that it touched its highest point at $4.65 and its lowest point at $2.94 during that stretch. It currently has a 1-year price target of $6.00. Beta for the stock currently stands at 0.83.

setenews.com     Nov 21, 2023

Investment News: Experts Favour Fixed Income Sector To Ride Out ... - Forbes

The Forbes Advisor editorial team is independent and objective. To help support our reporting work, and to continue our ability to provide this content for free to our readers, we receive payment from the companies that advertise on the Forbes Advisor site. This comes from two main sources.

Forbes     Nov 21, 2023